The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes

Related Experiment Videos

Insights

Somatostatin (SRIF) receptor binding is mediated by adenylate cyclase inhibition in pituitary tumor cells. Guanine nucleotides decrease SRIF receptor affinity, affecting dissociation kinetics and indicating receptor-mediated inhibition.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Molecular Pharmacology

Background:

  • Somatostatin (SRIF) inhibits vasoactive intestinal peptide (VIP)-stimulated cAMP accumulation in GH4C1 rat pituitary tumor cells.
  • This inhibition is crucial for SRIF's effect on VIP-stimulated hormone release.

Purpose of the Study:

  • To investigate the interaction between the SRIF receptor and adenylate cyclase in GH4C1 cell membranes.
  • To elucidate the mechanism of SRIF-mediated inhibition of VIP-stimulated adenylate cyclase activity.

Main Methods:

  • Measurement of adenylate cyclase activity in GH4C1 cell membranes.
  • Assessment of SRIF and analog potencies in inhibiting VIP-stimulated cAMP accumulation.
  • Analysis of [125I-Tyr1]SRIF binding kinetics in the presence and absence of guanine nucleotides.

Main Results:

  • SRIF noncompetitively inhibited VIP-stimulated adenylate cyclase activity without affecting basal activity.
  • SRIF receptor binding affinity was reduced by guanine nucleotides (GTP, Gpp(NH)p), indicating receptor-mediated inhibition.
  • Guanine nucleotides altered SRIF dissociation kinetics from biphasic to monophasic, suggesting a conformational change in the receptor-ligand complex.

Conclusions:

  • SRIF inhibition of adenylate cyclase in GH4C1 cells is receptor-mediated.
  • Guanine nucleotides play a critical role in modulating SRIF receptor affinity and dissociation kinetics.
  • These findings provide insights into the molecular mechanisms of somatostatin receptor signaling.

Related Concept Videos